Beyond Generics: India’s Journey to Global

This book argues that true leadership lies not in imitation, but in institution-building, innovation culture, and ethical courage.

Preface

Pharmaceutical leadership in the 21st century is no longer measured solely by tablet counts, export volumes, or regulatory approvals. It is measured by scientific originality, translational capability, ethical governance, patient-centric innovation, and national health sovereignty.

India’s pharmaceutical ecosystem today is paradoxical. On one hand, it supplies lifesaving medicines to over 200 countries; on the other, it depends heavily on imported active pharmaceutical ingredients, foreign clinical trial designs, and externally owned intellectual property. This duality—global relevance without global authority—defines the core challenge this book seeks to address.

Description

India stands at a decisive inflection point in its pharmaceutical journey. For over five decades, the nation has rightfully earned global recognition as the “Pharmacy of the World”—a title forged through scale, affordability, and an unmatched capability in generic medicines. Yet, this very success has become a strategic constraint. The global pharmaceutical order is rapidly shifting from volume-driven generics to innovation-led therapeutics, complex biologics, precision medicine, and knowledge-intensive healthcare solutions.

Despite possessing scientific talent, manufacturing depth, regulatory experience, and entrepreneurial energy, India remains underrepresented in new chemical entities (NCEs), original biologics, breakthrough medical technologies, and global intellectual property leadership. The question is no longer whether India can manufacture medicines cheaply—but whether India can discover, design, and define the medicines of the future.

This book is written to confront that question head-on.

Beyond Generics is not a celebratory account of past achievements, nor a pessimistic critique of current limitations. It is a strategic, ethical, scientific, and policy-oriented roadmap—intended to reframe India’s pharmaceutical ambition from a manufacturing powerhouse to a global healthcare thought leader.